While high-dose IL-2 has demonstrated durable efficacy in a subset of patients with metastatic melanoma and RCC, its severe toxicities, such as vascular leak syndrome and cytokine release syndrome, have limited its broader clinical application. The gene discussed is IL2; the disease is renal cell carcinoma.